Care Access Research has announced that it is collaborating with Eli Lilly and Company. Care Access Research is helping Lilly manage the system of decentralized, mobile clinical COVID-19 trials as part of the partnership. The BLAZE-2 phase III trial of Lilly's monoclonal antibody (mAb) LY-CoV555, has been initiated nationwide at nursing homes, a community proven to be especially vulnerable to SARS-COV2, the virus which causes COVID-19.
The trial is truly mobile with the deployment of traveling teams of trucks, RVs and personnel on the road simultaneously. Unlike virtual trials, the mobile research teams are capable of providing complex in-person patient care, including infusions, and have access to a fully functioning lab fitted with centrifuges, lab kits, and medical supplies that will help thousands of long-term facility residents and staff participate in this pivotal clinical trial. This unique model is scalable and implements innovative software and processes that aims to accelerate clinical trials, by making it easy to reach over 2,000 participants in a matter of months.
“COVID-19 has had a devastating impact on nursing home residents. We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals. While it's not easy to conduct clinical trials in this setting, we're taking on the challenge in an effort to help those who need us the most,” said Daniel Skovronsky, M.D., PhD, Lilly's chief scientific officer and president of Lilly Research Laboratories.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.